---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-116774"
form_type: "8-K"
ticker: "TBPH"
cik: "0001583107"
company_name: "Theravance Biopharma, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:55:47.001470+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Theravance Biopharma Q3 2024: YUPELRI sales record $62.2M (+7%); net loss widens; board forms strategic review

## Summary
- Total revenue $16.9M (Viatris collab); implied YUPELRI net sales $62.2M all-time high (7% YoY, 14% QoQ).
- Net loss $12.7M vs $9.0M YoY; non-GAAP net loss from operations $2.9M vs $0.7M.
- TRELEGY milestone: Q4 sales ~$260M needed for $25M payment, ~$610M for $50M; YTD sales $2.6B.
- Board forms Strategic Review Committee to assess alternatives to unlock shareholder value.
- CYPRESS (ampreloxetine) open-label enrollment on track for mid-2025 completion; data ~6 months later.

## SEC filing metadata
- accession: 0001104659-24-116774
- form_type: 8-K
- ticker: TBPH
- cik: 0001583107
- company_name: Theravance Biopharma, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583107/000110465924116774/0001104659-24-116774-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583107/000110465924116774/tm2428109d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-116774
- JSON: https://secwatch.observer/filing/0001104659-24-116774.json
- Plain text: https://secwatch.observer/filing/0001104659-24-116774.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.